Evidence map›Paper›PMID 33443635›Full record

ArticleApplied microbiology and biotechnology2021

Effect of temperature on the production of a recombinant antivenom in fed-batch mode.

Susana María Alonso Villela, Hazar Ghezal-Kraïem, Balkiss Bouhaouala-Zahar, Carine Bideaux, César Arturo Aceves Lara, Luc Fillaudeau

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Protective effect ofToxicon: X · 2026
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Susana María Alonso VillelaTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France. salonsovillela@gmail.com.ORCID http://orcid.org/0000-0001-8290-1635
Hazar Ghezal-KraïemLaboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur de Tunis, Université de Tunis El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0002-8180-0573
Balkiss Bouhaouala-ZaharLaboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur de Tunis, Université de Tunis El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0003-3147-245X
Carine BideauxTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.ORCID https://orcid.org/0000-0002-9830-5093
César Arturo Aceves LaraTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.
Luc FillaudeauTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.
Centre National de la Recherche Scientifique · FRTunis University · TN

Funding

Consejo Nacional de Ciencia y Tecnología 461347
6 · The paper itself

Abstract

In the pharmaceutical industry, nanobodies show promising properties for its application in serotherapy targeting the highly diffusible scorpion toxins. The production of recombinant nanobodies in Escherichia coli has been widely studied in shake flask cultures in rich medium. However, there are no upstream bioprocess studies of nanobody production in defined minimal medium and the effect of the induction temperature on the production kinetics. In this work, the effect of the temperature during the expression of the chimeric bispecific nanobody CH10-12 form, showing high scorpion antivenom potential, was studied in bioreactor cultures of E. coli. High biomass concentrations (25 g cdw/L) were achieved in fed-batch mode, and the expression of the CH10-12 nanobody was induced at temperatures 28, 29, 30, 33, and 37°C with a constant glucose feed. For the bispecific form NbF12-10, the induction was performed at 29°C. Biomass and carbon dioxide yields were reported for each culture phase, and the maintenance coefficient was obtained for each strain. Nanobody production in the CH10-12 strain was higher at low temperatures (lower than 30°C) and declined with the increase of the temperature. At 29°C, the CH10-12, NbF12-10, and WK6 strains were compared. Strains CH10-12 and NbF12-10 had a productivity of 0.052 and 0.021 mg/L/h of nanobody, respectively, after 13 h of induction. The specific productivity of the nanobodies was modeled as a function of the induction temperature and the specific growth rates. Experimental results confirm that low temperatures increase the productivity of the nanobody.Key points• Nanobodies with scorpion antivenom activity produced using two recombinant strains.• Nanobodies production was achieved in fed-batch cultures at different induction temperatures.• Low induction temperatures result in high volumetric productivities of the nanobody CH10-12.

Indexed as

AntiveninsEscherichia coliBatch Cell Culture TechniquesBioreactorsRecombinant ProteinsTemperatureAntiveninsRecombinant ProteinsEscherichia coliFed-batch strategyInduction temperatureKinetic modelingNanobodyRecombinant antivenom

Identifiers

PMID33443635
OpenAlexW3118455066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.